Skip to main content

FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease

The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a "clinical benefit" on a rare and aggressive form of the disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.